In practice, that means delisting its American Depositary Receipts (ADRs) from the Nasdaq, replacing them with a direct listing of ordinary shares on the New York Stock Exchange.GSK said Emma Walmsley, its CEO of nine years, who steered it through its demerger (its former consumer healthcare arm is now a separate company called Haleon), will leave at the end of the year. Her successor is Luke Miels, currently chief commercial officer, was poached from AZ amid acrimony eight years ago.There is an old British ...